

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mouritsen *et al.*

Appl. No.: 08/955,373

Filed: October 21, 1997

For: **Inducing Antibody Response  
Against Self-Proteins with the Aid  
of Foreign T-cell Epitopes**

Confirmation No.: 7254

Art Unit: 1644

Examiner: Schwadron, Ronald B.

Atty. Docket: 2473.0570003/EKS/LMB

**Second Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(c)**

***Mail Stop Amendment***

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO-1449, filed on May 23, 2002 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on November 2, 1999 in connection with the above-captioned application.

Further to the Examiner's comments in the Office Action dated September 9, 2005, Applicants submit this Second Supplemental Information Disclosure Statement to comply with 37 C.F.R. § 1.97(c) and include a statement as specified in 37 C.F.R. § 1.97(e) and the fee as set forth in 37 C.F.R. § 1.17(p). *See* paragraph 5, page 2 of Paper 200509. Applicants have not provided copies of the documents cited on the IDS Forms filed on May 23, 2002, but can provide copies of these documents at the Examiner's

request. Copies of the IDS Form, PTO-1449, filed on May 23, 2002 are enclosed for the Examiner's convenience.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Lori M. Brandes*

Lori M. Brandes  
Agent for Applicants  
Registration No. 57,772

Date: 10/10/06  
1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
593305v1

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO.	SERIAL NO.		
				674542-2004	08/955,373		
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT			
				Mouritsen et al.			
				FILING DATE	GROUP		
				October 21, 1997	1644		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,928,644	7/27/1999	Russell-Jones			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AB	WO 91/16683	10/31/1991	WIPO			YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AC		Etlinger, H.M. "Carrier sequence selection – one key to successful vaccines." <i>Immunology Today</i> 1992, 13(2):52-55.				
	AD		Dalum, I. et al., "Induction of Cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope." <i>Molecular Immunology</i> 1997, 34(16-17):1113-1120.				
	AE		Dalum, I. et al., "Therapeutic antibodies elicited by immunization against TNF- $\alpha$ ." <i>Nature Biotechnology</i> 1999, 17:666-669.				
	AF		Hertz, M. et al., "Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma." <i>The Journal of Immunology</i> 2001, 167:3792-3799.				
	AG		Hertz, M. et al., "Emerging therapeutic vaccines." <i>Drug Discovery World</i> 2000, Summer:49-53.				
	AH		Hertz, M. et al., "A therapeutic RANKL vaccine induces neutralizing anti-RANKL antibodies and prevents bone loss in ovariectomized mice." <i>ASBMR 23rd Annual Meeting Abstracts</i> , page S222. (Abstract)				
	AI		Juji, T., et al., "A novel therapeutic vaccine that prevents pathological bone destruction in models of osteoporosis and RA." <i>ASBMR 23rd Annual Meeting Abstracts</i> , page S223. (Abstract)				
	AJ		March 6, 2000 Press Release from M & E Biotech. "M & E Biotech licenses Autovac™ technology to Schering-Plough Animal Health."				
	AK		April 17, 2000 Press Release from M & E Biotech. "M & E Biotech A/S and H. Lundbeck A/S/ enter into a research and development agreement."				
	AL		May 31, 2000 Press Release from M & E Biotech. "Offer of shares in M & E Biotech subscribed 3 times."				
	AM		April 12, 2002 Press Release from M & E Biotech. "Pharmexa announces that GlaxoSmithKline has exclusive option on HER-2 protein breast cancer project."				
	AN		July 9, 2001 Press Release from M & E Biotech. "Pharmexa initiates phase I/II trials in breast cancer in Denmark."				
	AO		August 1, 2002 Press Release from M& E Biotech. "Pharmexa presents important pre-clinical data in its AutoVac™ HER-2 breast cancer programme."				
	AP		September 20, 2001 Press Release from M & E Biotech. "Pharmexa publishes important pre-clinical data in its AutoVac™ ILS asthma programme."				
	AQ		September 24, 2001 Press Release from M & E Biotech. "Pharmexa initiates phase I/II trial in breast cancer in the United Kingdom."				
	AR		December 17, 2001 Press Release from M & E Biotech. "Pharmexa announces AutoVac™ cancer license option."				
	AS		December 19, 2001 Press Release from M & E Biotech. "Positive change in Pharmexa's collaboration with Schering-Plough Animal Health."				
	AT		Birken, S. et al., "Structural and functional studies of the tryptic core of the human chorionic gonadotropin beta-subunit." <i>Endocrinology</i> 1987, 121(2):657-666. (Abstract)				
	AU		Crabb, J.W., et al., "Topological and epitope mapping of the cellular retinaldehyde-binding protein from retina." <i>J. Biological Chemistry</i> 1991, 266(25):16674-16683. (Abstract)				
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Based on Form PTO-1449 (3/90)			ATTY. DOCKET NO. <b>674542-2004</b>	SERIAL NO. <b>08/955,373</b>
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT <b>Mouritsen et al.</b>	
			FILING DATE <b>October 21, 1997</b>	GROUP <b>1644</b>
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
	AV		Gerity, E. and Conway, T.P. "Advantage of monoclonal vs. polyclonal antisera in a beta 2-microglobulin radioimmunoassay." <i>J. Immunological Methods</i> 1984, 68(1-2):131-135. (Abstract)	
	AW		Fabian, H. et al., "Comparative analysis of human and Dutch-type alzheimer beta-amyloid peptides by infrared spectroscopy and circular dichroism." <i>Biochem. Biophys. Res. Comm.</i> 1993, 191(1):232-239. (Abstract)	
	AX		Lamba, O.P. et al., "Estimation of the secondary structure and conformation of bovine lens crystallins by infrared spectroscopy: quantitative analysis and resolution by Fourier self-deconvolution and curve fit." <i>Biochim. Biophys. Acta.</i> 1993, 1163(2):113-123. (Abstract)	
	AY		Klaus, W. and Schomburg, D. "Solution structure of a variant of human pancreatic secretory trypsin inhibitor determined by nuclear magnetic resonance spectroscopy." <i>J. Molecular Biology</i> 1993, 229(3):695-706.	
EXAMINER			DATE CONSIDERED	
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				

.00068598